Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, Status and Forecast 2020-2026

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Asset Purchase
  • 1.4.3 Collaborative R&D
  • 1.4.4 Joint Venture
  • 1.4.5 Licensing
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2020 VS 2026
  • 1.5.2 Pharmaceutical Industry
  • 1.5.3 Biotechnology
  • 1.5.4 Medical Care
  • 1.5.5 Education and Research
  • 1.5.6 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2015-2026)
• 2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Regions
  • 2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Share by Regions (2015-2020)
  • 2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Cancer Monoclonal Antibody Partnering Terms and Agreements Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Market Size
  • 3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2015-2020)
  • 3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
  • 3.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2019
• 3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
• 3.4 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
• 3.5 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2015-2020)
• 4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2021-2026)

5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application (2015-2026)

• 5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
• 5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 6.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in North America (2019-2020)
• 6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 7.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Europe (2019-2020)
• 7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

8 China

• 8.1 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 8.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in China (2019-2020)
• 8.3 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 8.4 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 9.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Japan (2019-2020)
• 9.3 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 9.4 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 10.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 10.4 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

11 India

• 11.1 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 11.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in India (2019-2020)
• 11.3 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 11.4 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
• 12.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
• 12.4 Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 3SBio
  • 13.1.1 3SBio Company Details
  • 13.1.2 3SBio Business Overview and Its Total Revenue
  • 13.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020))
  • 13.1.5 3SBio Recent Development
• 13.2 4D Pharma
  • 13.2.1 4D Pharma Company Details
  • 13.2.2 4D Pharma Business Overview and Its Total Revenue
  • 13.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.2.5 4D Pharma Recent Development
• 13.3 Abbvie
  • 13.3.1 Abbvie Company Details
  • 13.3.2 Abbvie Business Overview and Its Total Revenue
  • 13.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.3.5 Abbvie Recent Development
• 13.4 Abzena
  • 13.4.1 Abzena Company Details
  • 13.4.2 Abzena Business Overview and Its Total Revenue
  • 13.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.4.5 Abzena Recent Development
• 13.5 Adaptive Biotechnologies
  • 13.5.1 Adaptive Biotechnologies Company Details
  • 13.5.2 Adaptive Biotechnologies Business Overview and Its Total Revenue
  • 13.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.5.5 Adaptive Biotechnologies Recent Development
• 13.6 Aeglea BioTherapeutics
  • 13.6.1 Aeglea BioTherapeutics Company Details
  • 13.6.2 Aeglea BioTherapeutics Business Overview and Its Total Revenue
  • 13.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.6.5 Aeglea BioTherapeutics Recent Development
• 13.7 Agenus Bio
  • 13.7.1 Agenus Bio Company Details
  • 13.7.2 Agenus Bio Business Overview and Its Total Revenue
  • 13.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.7.5 Agenus Bio Recent Development
• 13.8 Ascension
  • 13.8.1 Ascension Company Details
  • 13.8.2 Ascension Business Overview and Its Total Revenue
  • 13.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.8.5 Ascension Recent Development
• 13.9 Ascentage Pharma
  • 13.9.1 Ascentage Pharma Company Details
  • 13.9.2 Ascentage Pharma Business Overview and Its Total Revenue
  • 13.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.9.5 Ascentage Pharma Recent Development
• 13.10 Aslan Pharma
  • 13.10.1 Aslan Pharma Company Details
  • 13.10.2 Aslan Pharma Business Overview and Its Total Revenue
  • 13.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 13.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 13.10.5 Aslan Pharma Recent Development
• 13.11 Telix Pharmaceuticals
  • 10.11.1 Telix Pharmaceuticals Company Details
  • 10.11.2 Telix Pharmaceuticals Business Overview and Its Total Revenue
  • 10.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.11.5 Telix Pharmaceuticals Recent Development
• 13.12 Basilea Pharmaceutica
  • 10.12.1 Basilea Pharmaceutica Company Details
  • 10.12.2 Basilea Pharmaceutica Business Overview and Its Total Revenue
  • 10.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.12.5 Basilea Pharmaceutica Recent Development
• 13.13 Bavarian Nordic
  • 10.13.1 Bavarian Nordic Company Details
  • 10.13.2 Bavarian Nordic Business Overview and Its Total Revenue
  • 10.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.13.5 Bavarian Nordic Recent Development
• 13.14 Baxalta
  • 10.14.1 Baxalta Company Details
  • 10.14.2 Baxalta Business Overview and Its Total Revenue
  • 10.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.14.5 Baxalta Recent Development
• 13.15 Bayer
  • 10.15.1 Bayer Company Details
  • 10.15.2 Bayer Business Overview and Its Total Revenue
  • 10.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.15.5 Bayer Recent Development
• 13.16 Cantargia
  • 10.16.1 Cantargia Company Details
  • 10.16.2 Cantargia Business Overview and Its Total Revenue
  • 10.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.16.5 Cantargia Recent Development
• 13.17 Apollomics
  • 10.17.1 Apollomics Company Details
  • 10.17.2 Apollomics Business Overview and Its Total Revenue
  • 10.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.17.5 Apollomics Recent Development
• 13.18 Chiome Bioscience
  • 10.18.1 Chiome Bioscience Company Details
  • 10.18.2 Chiome Bioscience Business Overview and Its Total Revenue
  • 10.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.18.5 Chiome Bioscience Recent Development
• 13.19 Clovis Oncology
  • 10.19.1 Clovis Oncology Company Details
  • 10.19.2 Clovis Oncology Business Overview and Its Total Revenue
  • 10.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
  • 10.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
  • 10.19.5 Clovis Oncology Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer